Rates of hypoglycemia in users of sulfonylureas☆

https://doi.org/10.1016/S0895-4356(97)00024-3Get rights and content

Abstract

Objective. To identify the demographic and clinical characteristics of sulfonylurea users. To assess the risk of hypoglycemia in patients treated with sulfonylureas in clinical practice, and to characterize the risk in relation to the different drugs used.

Research design and methods. A cohort of 33,243 sulfonylurea users chosen from 719 clinical practices in the United Kingdom were identified through the VAMP-Research database. Information on demographic characteristics, medical diagnoses and use of medical services was obtained through the computerized records. For a stratified sample of 500 patients, general practioners completed a structured questionnaire on the duration, treatment, and complications of diabetes mellitus, obesity, alcohol use, and smoking history. Patients with a diagnosis of hypoglycemia, as recorded in the database within a time-window of a sulfonylurea prescription, were identified. Incidence rates per person-year of sulfonylurea therapy were estimated.

Results. Other than a longer duration of diabetes in users of chlorpropamide, no differences were observed among users of different sulfonylurea agents with respect to diabetic complications, adequacy of diabetic control, obesity, smoking, and excessive alcohol consumption. A diagnosis of hypoglycemia during sulfonylurea therapy was recorded in 605 people over 34,052 person-years of sulfonylurea therapy, which converted into an annual risk of 1.8%. The risk in glibenclamide users was higher than in users of other types of sulfonylureas uses. Duration of therapy, concomitant use of insulin, sulfonylurea-potentiating or antagonizing and concomitant use of betablockers were predictive of the risk of developing hypoglycemia.

Discussion. Drug use patterns showed comparability among users of different sulfonylurea agents. Our findings suggest that the rate of diagnosis of hypoglycemia made by physicians is higher for glibenclamide than for other sulfonylureas. An epidemiological study with objectively diagnosed hypoglycemia should be undertaken to confirm these results.

References (32)

  • HS Seltzer

    Drug induced hypoglycaemia, a review of 1418 cases

    Endocrinol Metab Clin North Am

    (1989)
  • BF Clarke et al.

    Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed maturity-onset diabetes

    Lancet

    (1975)
  • K Asplund et al.

    Glibenclamide-associated hypoglycaemia: A report on 57 cases

    Diabetologica

    (1983)
  • W Berger et al.

    Die relative Haeufigkeit der schweren Sulphonylharnstoff-Hypoglykaemie in den letzen 25 Jahren in der Schweiz

    Schweiz Med Wochenschr

    (1986)
  • AC Asmal et al.

    Oral hypoglycemic agents, an update

    Drugs

    (1984)
  • JE Jackson et al.

    Clinical pharmacology of sulphonylurea hypoglycemic agents: Part 1

    Drugs

    (1981)
  • JE Jackson et al.

    Clinical pharmacology of sulphonyl- urea hypoglycemic agents: Part 2

    Drugs

    (1981)
  • AW Logie et al.

    Drug interactions and long-term antidiabetic therapy

    Br J Clin Pharmacol

    (1976)
  • AM Jennings et al.

    Symptomatic hypoglycaemia in NDDM patients treated with oral hypoglycemic agents

    Diabetes Care

    (1989)
  • JM Stowers et al.

    Oral hypoglycemic drugs: Clinical pharmacology and therapeutic use

    Drugs

    (1977)
  • RE Ferner et al.

    Sulphonylureas and hypoglycaemia

    Br Med J

    (1988)

  • Multicentre study: UK prospective study of therapies of maturity onset diabetes

    Diabetologica

    (1983)
  • GC Hall et al.

    Postmarketing surveillance using a computerized general data base

    Pharmaceut Med

    (1988)
  • H Jick et al.

    Validation of information recorded on general practitioner based computerized data resource in the United Kingdom

    Br Med J

    (1991)
  • H Jick et al.

    Further validation of information recorded on general practitioner based computerized data resource in the United Kingdom

    Pharmacoepidemiol Drug Safety

    (1992)

    • Cited by (0)

    ☆

    Funds for this study were provided by Servier Canada.

    1

    Tjeerd van Staa is a former student of the Centre for Clinical Epidemiology and Community Studies at the Jewish General Hospital in Montreal.

    View full text
    Copyright © 1997 Published by Elsevier Inc.